Xoft, a developer of the Axxent Electronic Brachytherapy, eBx System, has reported that the clinical benefits of isotope-free electronic radiation therapy directly to cancer sites with minimal exposure to surrounding healthy tissue continues to be substantiated for multiple cancer treatments.

Xoft provides the systems for single-dose intraoperative radiation therapy (IORT) and accelerated brachytherapy applications.

The Targeted Intraoperative Radiation Therapy (TARGIT-A) Trial presented at the 46th Annual ASCO Meeting, is a randomized controlled trial designed to assess the equivalency of intraoperative radiotherapy with a single-dose against standard three to six week external beam radiotherapy after breast conserving surgery in women 45 years and over with invasive ductal carcinoma.

Xoft said that in the study, the 12-month results suggest that IORT utilising Xoft’s Electronic Brachytherapy is emerging as a patient and physician friendly alternative to Whole Radiation Therapy (WBRT) as well as APBI in a selected group of patients with early breast cancer.

At a mean follow-up of 12 months, overall results were encouraging with enhanced scores achieved in cosmesis and patient satisfaction. While long-term follow-up will continue, no recurrences have been observed to date.

The company said that the Axxent System, used for the treatment of early breast cancers, is also FDA-cleared for IORT and surface indications. It delivers non-radioactive therapy directly to cancer sites with minimal radiation exposure to surrounding healthy tissue.

The system also reduces the therapy time required from seven weeks, for external radiation therapy down to five days or a single dose for IORT, as it uses miniaturized X-ray source instead of a radioactive isotope.

Michael Klein, president and CEO of Xoft, said: “We commend the TARGIT researchers and are encouraged that the study continues to reinforce the clinical value of isotope-free electronic treatment for IORT and accelerated brachytherapy applications.

“We are pleased with the growing adoption of IORT for breast and other cancers and we strongly believe that continued research will further prove its ability to improve patient care and similarly catalyze continued adoption.”